Skip to main content
SpringerLink
Log in

Reply-Letter to the Editor: Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use

  • Letter to the Editor
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stowasser S, Quaresma M, Rieck M. Comment on: ‘Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use’. Drug Ther Perspect. 2018. https://doi.org/10.1007/s40267-018-0489-z.

  2. Lyseng-Williamson KA. Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use. Drugs Ther Perspect. 2018;234(1):8–15.

    Article  Google Scholar 

  3. Pan L, Belloni P, Ding HT, et al. A pharmacokinetic bioequivalence study comparing pirfenidone and capsule dosage forms in healthy adult volunteers. Adv Ther. 2017;34:2071–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Cottin V, Crestani B, Cadranel J, et al. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis—2017 update: full-length version. Rev Mal Respir. 2017;34(8):900–68.

    Article  PubMed  CAS  Google Scholar 

  5. Sköld CM, Bendstrup E, Myllärniemi M, et al. Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. J Intern Med. 2017;281(2):149–66.

    Article  PubMed  Google Scholar 

  6. Xaubet A, Molina-Molina M, Acosta O, et al. Guidelines for the medical treatment of idiopathic pulmonary fibrosis. Arch Bronconeumol. 2017;53(5):263–9.

    Article  PubMed  Google Scholar 

  7. Ofev (nintedanib): summary of product characteristics. London: European Medicines Agency; 2017.

  8. Esbriet (pirfenidone) tablets and capsules: summary of product characteristics. London: European Medicines Agency; 2017.

  9. Keating GM. Nintedanib in idiopathic pulmonary fibrosis: a guide to its use. Drugs Ther Perspect. 2015;31(10):329–33.

  10. Dhillon S. Nintedanib in advanced NSCLC of adenocarcinoma histology: a guide to its use. Drugs Ther Perspect. 2018. https://doi.org/10.1007/s40267-018-0481-7.

Download references

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this reply was not supported by any external funding.

Conflict of interest

K.A. Lyseng-Williamson is an employee of Adis/Springer, is responsible for the content of the reply and declares no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. Reply-Letter to the Editor: Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use. Drugs Ther Perspect 34, 194–195 (2018). https://doi.org/10.1007/s40267-018-0488-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-018-0488-0

Search

Navigation